Spots Global Cancer Trial Database for adebrelimab
Every month we try and update this database with for adebrelimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) | NCT06251492 | Prostate Cancer... Castration-resi... | Stereotactic bo... Adebrelimab | 18 Years - 75 Years | Fudan University | |
| A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors | NCT05942378 | Advanced Solid ... | HRXG-K-1939 Adebrelimab | 18 Years - 75 Years | Fudan University | |
| Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino | NCT06156267 | Pancreatic Canc... | Adebrelimab mRNA tumor vacc... | 18 Years - 75 Years | Fudan University | |
| Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT06208462 | Intrahepatic Ch... | Adebrelimab Lenvatinib Gemcitabine Oxaliplatin | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer | NCT06102772 | Gastric Cancer | Adebrelimab，Fru... | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer | NCT06267170 | SCLC,Extensive ... | Adebrelimab | 18 Years - | Henan Cancer Hospital | |
| Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer | NCT06427239 | Pancreatic Canc... | HRS-4642 Adebrelimab | 18 Years - 75 Years | Fudan University | |
| Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma | NCT05924997 | Advanced Hepato... | adebrelimab, ca... | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer | NCT06433609 | Advanced Breast... | SHR-A1811 SHR-A1921 Adebrelimab | 18 Years - 75 Years | Beijing GoBroad Hospital | |
| Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma | NCT06339619 | Locally Advance... | Adebrelimab Apatinib Tegafur | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | NCT06229067 | Breast Cancer Triple Negative... | Adebrelimab Vinorelbine Cyclophosphamid... Capecitabine | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer | NCT06427239 | Pancreatic Canc... | HRS-4642 Adebrelimab | 18 Years - 75 Years | Fudan University | |
| A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation | NCT06385678 | Advanced KRAS G... | HRS-4642 Adebrelimab SHR-A1921 Pemetrexed Diso... | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT06208462 | Intrahepatic Ch... | Adebrelimab Lenvatinib Gemcitabine Oxaliplatin | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC) | NCT06320301 | Biliary Tract C... Gemox Chemother... | Adebrelimab + G... | - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC | NCT06375642 | Intrahepatic Ch... | Adebrelimab | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Adebrelimab and Chemoradiotherapy in High-risk Locoregionally Advanced Nasopharyngeal Carcinoma | NCT06349889 | Nasopharyngeal ... Nasopharyngeal ... | Adebrelimab | 18 Years - 65 Years | Sun Yat-sen University | |
| Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) | NCT06251492 | Prostate Cancer... Castration-resi... | Stereotactic bo... Adebrelimab | 18 Years - 75 Years | Fudan University | |
| Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma | NCT05444088 | Advanced Hepato... | Adebrelimab Bevacizumab SHR-8068 | 18 Years - 75 Years | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | |
| Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC) | NCT06320301 | Biliary Tract C... Gemox Chemother... | Adebrelimab + G... | - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma | NCT06339619 | Locally Advance... | Adebrelimab Apatinib Tegafur | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | NCT06229067 | Breast Cancer Triple Negative... | Adebrelimab Vinorelbine Cyclophosphamid... Capecitabine | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis | NCT06418594 | HER2-negative B... | Adebrelimab Apatinib Etoposide | 18 Years - | Beijing 302 Hospital | |
| The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma | NCT06266832 | Rectal Adenocar... | Adebrelimab Oxaliplatin Capecitabine Short-course Ra... Biopsy | 18 Years - | Sir Run Run Shaw Hospital | |
| Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma | NCT05970666 | Adebrelimab Hepatocellular ... Transformation Bevacizumab TACE | TACE with adebr... | 18 Years - 75 Years | The First Affiliated Hospital of Xiamen University | |
| Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | NCT06298968 | Intrahepatic Ch... | combined therap... | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer. | NCT05753826 | Ovarian Neoplas... Ovarian Disease... | Adebrelimab Fuzuloparib | 18 Years - 70 Years | Fujian Cancer Hospital | |
| A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC | NCT06424899 | Non Small Cell ... | Adebrelimab radical chemora... Platinum based ... | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer | NCT06282445 | Colorectal Canc... | Adebrelimab Oxaliplatin Capecitabine Bevacizumab | 18 Years - 75 Years | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | |
| Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer | NCT06149767 | Cervical Cancer | Adebrelimab | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed | NCT06102759 | Gastric Cancer | Adebrelimab，Fru... | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401) | NCT06261125 | Hepatocellular ... | Stereotactic bo... Adebrelimab Lenvatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations | NCT06299371 | Non Small Cell ... | Adebrelimab paclitaxel for ... Cisplatin or Ca... | 18 Years - | Liaoning Tumor Hospital & Institute | |
| A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC | NCT06424899 | Non Small Cell ... | Adebrelimab radical chemora... Platinum based ... | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies | NCT06181032 | Biliary Tract M... | Adebrelimab Apatinib Gemcitabine Cisplatin | 18 Years - 75 Years | First Affiliated Hospital of Fujian Medical University | |
| A Prospective, Single-arm, Multicenter Phase II Clinical Study of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma | NCT06405061 | Adebrelimab Hepatocellular ... | Adebrelimab | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer | NCT06236997 | Small Cell Lung... | Adebrelimab Radiation Thera... etoposide, carb... | 18 Years - 75 Years | Henan Cancer Hospital | |
| HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer | NCT06389500 | Biliary Tract C... | Adebrelimab Lenvatinib Hepatic Arteria... | 18 Years - 75 Years | Harbin Medical University | |
| Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma | NCT06198465 | Adebrelimab Esophageal Canc... Perioperative P... | adebrelimab,Pac... | 18 Years - | Xijing Hospital | |
| Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC) | NCT06320301 | Biliary Tract C... Gemox Chemother... | Adebrelimab + G... | - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Adebrelimab and Chemoradiotherapy in High-risk Locoregionally Advanced Nasopharyngeal Carcinoma | NCT06349889 | Nasopharyngeal ... Nasopharyngeal ... | Adebrelimab | 18 Years - 65 Years | Sun Yat-sen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
